机构:[1]Capital Med Univ, Beijing Shijitan Hosp, Dept Gastrointestinal Surg, Dept Clin Nutr, Beijing, Peoples R China[2]Capital Med Univ, Xuanwu Hosp, Natl Clin Res Ctr Geriatr Dis, Beijing, Peoples R China首都医科大学宣武医院[3]Key Lab Canc FSMP State Market Regulat, Beijing, Peoples R China[4]Capital Med Univ, Beijing Friendship Hosp, Dept Gen Surg, Beijing, Peoples R China首都医科大学附属北京友谊医院[5]Sun Yat Sen Univ, Affiliated Hosp 1, Ctr Gastrointestinal Surg, Guangzhou, Peoples R China中山大学附属第一医院[6]Yunnan Univ, Kunming, Yunnan, Peoples R China[7]Gen Surg Clin Med Ctr Yunnan Prov, Kunming, Peoples R China[8]Sichuan Univ, West China Hosp, Dept Clin Nutr, Chengdu, Peoples R China四川大学华西医院[9]Chinese Acad Med Sci & Peking Union Med Coll, Canc Hosp, Natl Canc Ctr, Dept Comprehens Oncol, Beijing, Peoples R China[10]Guangxi Med Univ, Sch Preclin Med, Dept Immunol, Nanning, Peoples R China
BackgroundThe development and progression of cancer cachexia are connected to systemic inflammation and physical performance. However, few relevant studies have reported the survival outcomes prediction of systemic inflammation and physical performance in patients with colorectal cancer (CRC) cachexia. This study investigated the prognostic prediction value of systemic inflammation and performance status in patients with CRC cachexia.MethodsThis multicentre cohort study prospectively collected 905 patients with CRC (58.3% males, 59.3 +/- 11.5 years old). Cancer cachexia was diagnosed according to the 2011 Fearon Cachexia Diagnostic Consensus. The prognostic value of systematic inflammatory indicators was determined using the area under the curve, concordance index, and multivariate survival analysis. Performance status was evaluated with Eastern Coopertive Oncology Group performance score (ECOG-PS). Survival data were analysed using univariate and multivariate Cox regression analyses.ResultsThe area under the curve, concordance index and survival analysis showed that C-reactive protein (CRP), lymphocyte to CRP ratio (LCR) and CRP to albumin ratio (CAR) were more stable and consistent with the survival of patients with CRC, both in non-cachexia and cachexia populations. Among patients with CRC cachexia, high inflammation [low LCR, hazard ratio (HR) 95% confidence interval (95% CI) = 3.33 (2.08-5.32); high CAR, HR (95% CI) = 2.92 (1.88-4.55); high CRP, HR (95% CI) = 3.12 (2.08-4.67)] indicated a worse prognosis, compared with non-cachexia patients [low LCR, HR (95% CI) = 2.28 (1.65-3.16); high CAR, HR (95% CI) = 2.36 (1.71-3.25); high CRP, HR (95% CI) = 2.58 (1.85-3.60)]. Similarly, among patients with CRC cachexia, high PS [ECOG-PS 2, HR (95% CI) = 1.61 (1.04-2.50); ECOG-PS 3/4, HR (95% CI) = 2.91 (1.69-5.00]) indicated a worse prognosis, compared with patients with CRC without cachexia [ECOG-PS 2, HR (95% CI) = 1.28 (0.90-1.81); ECOG-PS 3/4, HR (95% CI) = 2.41 (1.32-4.39]). Patients with CRC cachexia with an ECOG-PS score of 2 or 3-4 and a high inflammation had a shorter median survival time, compared with patients with an ECOG-PS score of 0/1 and a low inflammation.ConclusionsThe systemic inflammatory markers LCR, CAR and CRP have stable prognostic values in patients with CRC. The ECOG-PS may be an independent risk factor for CRC. Combined evaluation of systemic inflammation and ECOG-PS in patients with CRC cachexia could provide a simple survival prediction.
基金:
We all appreciate the support from the National Key Research and Development Program (grant number 2017YFC1309200 and 2022YFC2009600) and the Beijing Municipal Science and Technology Commission (grant number SCW2018-06). We would like to thank Editage () f [2017YFC1309200, 2022YFC2009600]; National Key Research and Development Program [SCW2018-06]; Beijing Municipal Science and Technology Commission
语种:
外文
被引次数:
WOS:
PubmedID:
中科院(CAS)分区:
出版当年[2022]版:
大类|1 区医学
小类|1 区老年医学1 区医学:内科
最新[2023]版:
大类|1 区医学
小类|1 区老年医学1 区医学:内科
JCR分区:
出版当年[2021]版:
Q1GERIATRICS & GERONTOLOGYQ1MEDICINE, GENERAL & INTERNAL
最新[2023]版:
Q1MEDICINE, GENERAL & INTERNALQ1GERIATRICS & GERONTOLOGY
第一作者机构:[1]Capital Med Univ, Beijing Shijitan Hosp, Dept Gastrointestinal Surg, Dept Clin Nutr, Beijing, Peoples R China[2]Capital Med Univ, Xuanwu Hosp, Natl Clin Res Ctr Geriatr Dis, Beijing, Peoples R China[3]Key Lab Canc FSMP State Market Regulat, Beijing, Peoples R China[4]Capital Med Univ, Beijing Friendship Hosp, Dept Gen Surg, Beijing, Peoples R China
通讯作者:
通讯机构:[1]Capital Med Univ, Beijing Shijitan Hosp, Dept Gastrointestinal Surg, Dept Clin Nutr, Beijing, Peoples R China[2]Capital Med Univ, Xuanwu Hosp, Natl Clin Res Ctr Geriatr Dis, Beijing, Peoples R China[3]Key Lab Canc FSMP State Market Regulat, Beijing, Peoples R China[10]Guangxi Med Univ, Sch Preclin Med, Dept Immunol, Nanning, Peoples R China[*1]Department of Gastrointestinal Surgery, Department of Clinical Nutrition, Beijing Shijitan Hospital, Capital Medical University, Key Laboratory of Cancer FSMP for State Market Regulation, 10 Tie Yi Road. Beijing 100038, China.[*2]Department of Immunology, School of Preclinical Medicine, Guangxi Medical University, Nanning 530021, China.
推荐引用方式(GB/T 7714):
Ruan Guo-Tian,Xie Hai-Lun,Yuan Kai-Tao,et al.Prognostic value of systemic inflammation and for patients with colorectal cancer cachexia[J].JOURNAL OF CACHEXIA SARCOPENIA AND MUSCLE.2023,14(6):2813-2823.doi:10.1002/jcsm.13358.
APA:
Ruan, Guo-Tian,Xie, Hai-Lun,Yuan, Kai-Tao,Lin, Shi-Qi,Zhang, He-Yang...&Shi, Han-Ping.(2023).Prognostic value of systemic inflammation and for patients with colorectal cancer cachexia.JOURNAL OF CACHEXIA SARCOPENIA AND MUSCLE,14,(6)
MLA:
Ruan, Guo-Tian,et al."Prognostic value of systemic inflammation and for patients with colorectal cancer cachexia".JOURNAL OF CACHEXIA SARCOPENIA AND MUSCLE 14..6(2023):2813-2823